FY2024 Earnings Estimate for PLX Issued By HC Wainwright

Posted by Jeff Wilder on Feb 5th, 2025

Protalix BioTherapeutics, Inc. (NYSE:PLX – Free Report) – HC Wainwright issued their FY2024 earnings per share (EPS) estimates for Protalix BioTherapeutics in a note issued to investors on Monday, February 3rd. HC Wainwright analyst R. Selvaraju expects that the company will post earnings of $0.01 per share for the year. HC Wainwright has a “Buy” rating and a $15.00 price objective on the stock. The consensus estimate for Protalix BioTherapeutics’ current full-year earnings is $0.02 per share. HC Wainwright also issued estimates for Protalix BioTherapeutics’ Q4 2024 earnings at $0.06 EPS and FY2025 earnings at $0.19 EPS.

Separately, StockNews.com lowered Protalix BioTherapeutics from a “strong-buy” rating to a “buy” rating in a research report on Tuesday.

Read Our Latest Analysis on PLX

Protalix BioTherapeutics Price Performance

Shares of NYSE PLX opened at $2.52 on Wednesday. Protalix BioTherapeutics has a 52-week low of $0.82 and a 52-week high of $2.54. The business’s 50 day moving average is $2.01 and its two-hundred day moving average is $1.43.

Institutional Trading of Protalix BioTherapeutics

A number of large investors have recently modified their holdings of the stock. Y Intercept Hong Kong Ltd purchased a new stake in shares of Protalix BioTherapeutics during the fourth quarter worth $35,000. PFG Investments LLC purchased a new stake in shares of Protalix BioTherapeutics during the fourth quarter worth $39,000. Cubist Systematic Strategies LLC purchased a new stake in shares of Protalix BioTherapeutics during the second quarter worth $37,000. GSA Capital Partners LLP increased its position in shares of Protalix BioTherapeutics by 8.5% during the third quarter. GSA Capital Partners LLP now owns 435,213 shares of the company’s stock worth $444,000 after acquiring an additional 33,969 shares during the period. Finally, XTX Topco Ltd purchased a new stake in shares of Protalix BioTherapeutics during the third quarter worth $36,000. Hedge funds and other institutional investors own 16.53% of the company’s stock.

Protalix BioTherapeutics Company Profile

(Get Free Report)

Protalix BioTherapeutics, Inc, a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.